Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

323
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
323
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

335
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
335
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Culmerciclib: First Approval.

Drugs·2026
Same author

Plozasiran: First Approval.

Drugs·2026
Same author

Donidalorsen: First Approval.

Drugs·2025
Same author

Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults.

CNS drugs·2025
Same author

Lisaftoclax: First Approval.

Drugs·2025
Same author

Clesrovimab: First Approval.

Drugs·2025

関連する実験動画

Updated: Feb 17, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Puzolcabtagene Autoleucel:小児科初の承認について

Yahiya Y Syed1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.

Paediatric drugs
|February 16, 2026
PubMed
まとめ
この要約は機械生成です。

新しいCAR T細胞療法であるPuzolcabtagene autoleucelは,中国で若年患者の再発または耐性B細胞急性リンパ性白血病の治療に承認されました. このセラピーは,がん治療の強化のためにCD19陽性細胞を標的とする.

さらに関連する動画

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

574

関連する実験動画

Last Updated: Feb 17, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

574

科学分野:

  • 腫瘍学 腫瘍学
  • 免疫療法による免疫療法です.
  • セルラーセラピー 細胞療法

背景:

  • 化学抗原受容体 (CAR) T細胞治療は,パーソナライズされたがん治療における重要な進歩を表しています.
  • CAR T細胞治療は,B細胞悪性腫瘍のような癌細胞を標的とし破壊するために患者のT細胞を遺伝子工学的に設計することを含む.
  • Puzolcabtagene autoleucelは,B細胞急性リンパ性白血病 (B-ALL) および他のB細胞リンパ腫のために開発された革新的な自主CAR T細胞療法です.

研究 の 目的:

  • Puzolcabtagene autoleucel.の発達のマイルストーンを要約すると,
  • 中国でパゾルカバテゲン・オートルユケルの最初の規制承認を強調するために.
  • B細胞悪性腫瘍に対するこの新しいCAR T細胞療法について概要を述べる.

主な方法:

  • オトログで人間化された抗CD19 CAR T細胞製品の開発.
  • エンジニアリングT細胞は,CD19抗原を標的としたCARを発現させ,免疫原性を最小限に抑えるために人間化された単鎖変数断片を組み込む.
  • CD19陽性の再発性または耐性B細胞急性リンパ性白血病の治療のための臨床評価.

主要な成果:

  • Puzolcabtagene autoleucelは,2025年11月4日に中国で初めて規制承認を受けました.
  • 承認は,CD19陽性再発性または耐性B細胞急性リンパ性白血病 (R/R B-ALL) の3歳から21歳までの患者の治療のためのものです.
  • この治療は,直接的な細胞毒性,アポトーシス誘導,およびTNFリガンド媒介経路を用いて,がん細胞の除去を図る.

結論:

  • Puzolcabtagene autoleucelは,中国の特定の小児および若年成人集団におけるR/R B-ALLの重要な治療選択肢を示しています.
  • Puzolcabtagene autoleucelの開発は,血液学的悪性腫瘍に対するCAR T細胞療法における進歩を強調しています.
  • この承認は,B細胞がんに対するパーソナライズされた免疫療法の臨床翻訳における重要なマイルストーンを示しています.